Perioperative use of NSAID might prevent early relapses in breast and other cancers: An upstream approach

Joint Event on 27^th World Oncologists Annual Conference on Medical Oncology, Radiation Oncology & Surgical Oncology & 10^th International Conference on Dermatology & Cosmetology

December 07-08, 2018 | Chicago, USA

Michael Retsky

Harvard TH Chan School of Public Health, USA

Keynote: J Oncol Transl Res

Abstract :

A bimodal pattern of the hazard of relapse among early-stage breast cancer patients has been identified in multiple databases from US, Europe, and Asia. We are studying these data to determine if this can lead to new ideas on how to prevent relapse in breast cancer. Using computer simulation and access to a very high-quality database from Milan for patients treated with mastectomy only, we proposed that relapses within 3 years of surgery are stimulated somehow by the surgical procedure. Most relapses in breast cancer are in this early category. Retrospective data from a Brussels anesthesiology group suggests a plausible mechanism. Use of ketorolac, a common NSAID analgesic occasionally used in surgery was associated with far superior diseasefree survival in the first 5 years after surgery. The expected prominent early relapse events in months 9-18 are reduced 5-fold. Transient systemic inflammation accompanying surgery (identified by IL-6 in serum) could facilitate angiogenesis of dormant micrometastases, the proliferation of dormant single cells, and seeding of circulating cancer stem cells (perhaps in part released from bone marrow) resulting in early relapse and could have been effectively blocked by the perioperative anti-inflammatory agent. If this observation holds up to further scrutiny, it could mean that the simple use of this safe, inexpensive and effective anti-inflammatory agent at surgery might eliminate early relapses. We suggest this would be most effective for triple negative breast cancer and be especially valuable in low and middle-income countries. Similar bimodal patterns have been identified in other cancers suggesting a general effect.

Biography :

Michael Retsky (PhD in Physics from the University of Chicago) made a career change to cancer research thirty years ago. He is on staff at Harvard TH Chan School of Public Health and faculty at University College London. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. He is an Editor of Nature/ Springer book on the breast cancer project published July 2017. He was the first person to use what is now called metronomic adjuvant chemotherapy and is a founder and for 10 years was on the Board of Directors of the Colon Cancer Alliance. He has published more than 60 papers in physics and cancer.

E-mail: mretsky@hsph.harvard.edu